TC BioPharm, a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer, has chosen Fortrea as its Contract Research Organization (CRO) for conducting global trials, including ACHIEVE and ACHIEVE2, in the UK and US respectively. Fortrea will oversee the management of these trials on an ongoing basis, establishing a vertically integrated clinical trial program. This integration is expected to enhance operational efficiencies, leading to improved data management and review, as well as increased value creation. By consolidating CRO services under a single entity, TC BioPharm anticipates generating cost savings.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!